Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer

PURPOSE: Trop-2, expressed in most triple-negative breast cancers (TNBCs), may be a potential target for antibody-drug conjugates. Sacituzumab govitecan, an antibody-drug conjugate, targets Trop-2 for the selective delivery of SN-38, the active metabolite of irinotecan. PATIENTS AND METHODS: We eval...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Bardia, Aditya, Mayer, Ingrid A., Diamond, Jennifer R., Moroose, Rebecca L., Isakoff, Steven J., Starodub, Alexander N., Shah, Nikita C., O’Shaughnessy, Joyce, Kalinsky, Kevin, Guarino, Michael, Abramson, Vandana, Juric, Dejan, Tolaney, Sara M., Berlin, Jordan, Messersmith, Wells A., Ocean, Allyson J., Wegener, William A., Maliakal, Pius, Sharkey, Robert M., Govindan, Serengulam V., Goldenberg, David M., Vahdat, Linda T.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2017
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5559902/
https://ncbi.nlm.nih.gov/pubmed/28291390
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2016.70.8297
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados